MAGEA3 and melanoma: Similarly, a signature derived from MAGE-A3 vaccination therapy [37] was significantly associated with Immunotype-1 tumors (Fig. 4H-I) and, correspondingly, a majority of samples from melanoma patients responding to MAGE-A3 vaccination were significantly enriched for the Immunotype-1 signature.